Lupus & antiphospholipid syndrome
Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus
Authors' conclusion
Our study illuminate serum RIPK3/MLKL proteins are exploratory biomarker candidates for SLE and necroptosis may be involved in SLE pathogenesis.
Study context
- Population
- SLE patients and healthy controls
- Participants
- 90 vs 50
- Comparison
- SLE vs healthy controls (HC)
- SLEn = 90
- HCn = 50reference
- Outcome
- Serum RIPK3/MLKL protein levels (enzyme-linked immune sorbent assay (ELISA))
Main finding
As reported in the abstract
Serum RIPK3/MLKL protein levels
- SLE vs HC: P = 0.0004
- SLE vs HC: P = 0.0005
Observational data: associations, not effects.
Further findings
| Outcome | RIPK3 | MLKL |
|---|---|---|
| Diagnostic performance (ROC) | ||
| AUC | 0.6319 | 0.7374 |
| P | p = 0.0099 | p < 0.0001 |
- RIPK3/MLKL in active vs stable SLE · higher in active SLE
- P = 0.0312
- RIPK3/MLKL in active vs stable SLE · higher in active SLE
- P = 0.0096
- RIPK3 in lupus nephritis (LN) vs non-LN · significant upregulation in LN
- P = 0.0017
- RIPK3 by anti-nuclear antibody (ANA) titer · High ANA titers vs Low ANA titers · higher with high ANA titers
- P < 0.0001
Original publication
Serum RIPK3/MLKL as exploratory biomarker candidates for systemic lupus erythematosus. Lupus. Published 23 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →